# Eitan Friedman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5623686/publications.pdf

Version: 2024-02-01

| 217 | 12,320 | 50244 | 29127 |
|---|---|---|---|
| papers | citations | 46 h-index | 104 g-index |

| 222 | 222 | 222 | 16126 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Activating Mutations of the Stimulatory G Protein in the McCuneâ€“Albright Syndrome. New England Journal of Medicine, 1991, 325, 1688-1695. | 13.9 | 1,804 |
| 2 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384. | 9.4 | 493 |
| 3 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347. | 3.8 | 390 |
| 4 | Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2001, 345, 235-240. | 13.9 | 370 |
| 5 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691. | 9.4 | 356 |
| 6 | Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779. | 3.0 | 318 |
| 7 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892. | 9.4 | 309 |
| 8 | International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2008, 122, 2017-2022. | 2.3 | 306 |
| 9 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778. | 9.4 | 289 |
| 10 | Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14205-14210. | 3.3 | 286 |
| 11 | Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4340-4345. | 3.3 | 274 |
| 12 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581. | 9.4 | 265 |
| 13 | Autosomal Recessive Catecholamine- or Exercise-Induced Polymorphic Ventricular Tachycardia. Circulation, 2001, 103, 2822-2827. | 1.6 | 257 |
| 14 | Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948. | 2.6 | 257 |
| 15 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212. | 1.5 | 244 |
| 16 | Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620. | 1.1 | 224 |
| 17 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171. | 9.4 | 221 |
| 18 | Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995. | 9.4 | 218 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200. | 2.6 | 217 |
| 20 | Abraham's Children in the Genome Era: Major Jewish Diaspora Populations Comprise Distinct Genetic Clusters with Shared Middle Eastern Ancestry. American Journal of Human Genetics, 2010, 86, 850-859. | 2.6 | 217 |
| 21 | Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499. | 0.9 | 195 |
| 22 | Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842. | 0.9 | 148 |
| 23 | Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99. | 0.9 | 142 |
| 24 | Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504. | 9.4 | 138 |
| 25 | The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 2007, 104, 7-10. | 0.6 | 135 |
| 26 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386. | 9.4 | 125 |
| 27 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73. | 9.4 | 120 |
| 28 | Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish highâ€risk women. International Journal of Cancer, 2010, 127, 589-597. | 2.3 | 116 |
| 29 | Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173. | 1.5 | 105 |
| 30 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375. | 5.8 | 93 |
| 31 | Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist, 2017, 22, 804-810. | 1.9 | 91 |
| 32 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741. | 5.8 | 90 |
| 33 | Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431. | 5.8 | 88 |
| 34 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666. | 1.1 | 82 |
| 35 | Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3770-3774. | 3.3 | 81 |
| 36 | Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47. | 1.3 | 81 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Letters, 2007, 257, 236-243. | 3.2 | 78 |
| 38 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675. | 5.8 | 78 |
| 39 | Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson Disease. JAMA Neurology, 2015, 72, 58. | 4.5 | 76 |
| 40 | Lessons learned â€" resolving the enigma of genetic factors in IBS. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 77-87. | 8.2 | 76 |
| 41 | Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197. | 0.8 | 76 |
| 42 | BRCA mutation carriers show normal ovarian response in inÂvitro fertilization cycles. Fertility and Sterility, 2015, 104, 1162-1167. | 0.5 | 75 |
| 43 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430. | 0.4 | 54 |
| 44 | Comparative Genomic Hybridization Analysis of Nonfunctioning Pituitary Tumors<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1801-1805. | 1.8 | 53 |
| 45 | Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertility and Sterility, 2015, 103, 1305-1312. | 0.5 | 51 |
| 46 | Mutational analyses ofBRCA1 andBRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Human Mutation, 2000, 16, 491-501. | 1.1 | 50 |
| 47 | Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218. | 3.4 | 48 |
| 48 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256. | 1.5 | 47 |
| 49 | Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clinical Endocrinology, 1997, 47, 707-712. | 1.2 | 46 |
| 50 | CHEK2*1100delC and male breast cancer risk in Israel. International Journal of Cancer, 2004, 108, 479-480. | 2.3 | 46 |
| 51 | Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers. Breast Cancer Research, 2006, 8, R15. | 2.2 | 44 |
| 52 | Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. European Journal of Human Genetics, 2013, 21, 212-216. | 1.4 | 44 |
| 53 | Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Research and Treatment, 2016, 157, 157-165. | 1.1 | 43 |
| 54 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112. | 2.2 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma. International Journal of Gynecological Cancer, 2010, 20, 1148-1153. | 1.2 | 41 |
| 56 | Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection. Molecular and Cellular Proteomics, 2019, 18, 865a-875. | 2.5 | 41 |
| 57 | Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2009, 116, 195-200. | 1.1 | 38 |
| 58 | Genotype phenotype correlations in Israeli colorectal cancer patients. International Journal of Cancer, 2005, 114, 58-73. | 2.3 | 37 |
| 59 | COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases. Academic Radiology, 2021, 28, 1191-1197. | 1.3 | 36 |
| 60 | Genetic and biochemical analyses of Israeli osteogenesis imperfecta patients. Human Mutation, 2004, 23, 399-400. | 1.1 | 35 |
| 61 | Genetic Analyses of Male Breast Cancer in Israel. Genetic Testing and Molecular Biomarkers, 2000, 4, 313-317. | 1.7 | 34 |
| 62 | Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020. | 1.1 | 34 |
| 63 | Inter- and intra-lesional molecular heterogeneity of oral leukoplakia. Oral Oncology, 2015, 51, 178-181. | 0.8 | 34 |
| 64 | The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23. | 1.1 | 34 |
| 65 | Genetic analysis of familial colorectal cancer in Israeli Arabs. Human Mutation, 2003, 21, 446-447. | 1.1 | 32 |
| 66 | Cutaneous malignant melanoma and Parkinson disease: Common pathways?. Annals of Neurology, 2016, 80, 811-820. | 2.8 | 32 |
| 67 | Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468. | 0.6 | 32 |
| 68 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64. | 2.2 | 31 |
| 69 | Functional polymorphisms in the P2X7 receptor gene are associated with stress fracture injury. Purinergic Signalling, 2016, 12, 103-113. | 1.1 | 31 |
| 70 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364. | 3.0 | 30 |
| 71 | Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Familial Cancer, 2012, 11, 483-491. | 0.9 | 29 |
| 72 | Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers. Breast Cancer Research and Treatment, 2013, 138, 753-760. | 1.1 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. Cancer Genetics, 2016, 209, 70-74. | 0.2 | 29 |
| 74 | Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Familial Cancer, 2015, 14, 383-391. | 0.9 | 28 |
| 75 | Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement Disorders, 2019, 34, 1392-1398. | 2.2 | 28 |
| 76 | Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer, 2019, 125, 698-703. | 2.0 | 28 |
| 77 | Could the 185delAG BRCA1 Mutation Be an Ancient Jewish Mutation?. European Journal of Human Genetics, 1997, 5, 413-416. | 1.4 | 28 |
| 78 | The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. Public Health Genomics, 2001, 4, 50-55. | 0.6 | 27 |
| 79 | Two p16 (CDKN2A) germline mutations in 30ÂIsraeli melanoma families. European Journal of Human Genetics, 2000, 8, 590-596. | 1.4 | 26 |
| 80 | The I1307KAPCPolymorphism: Prevalence in Non-Ashkenazi Jews and Evidence for a Founder Effect. Genetic Testing and Molecular Biomarkers, 2001, 5, 141-146. | 1.7 | 26 |
| 81 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61. | 2.2 | 26 |
| 82 | An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327. | 1.1 | 26 |
| 83 | Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Research and Treatment, 2011, 127, 489-495. | 1.1 | 25 |
| 84 | The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. Cancer, 2001, 92, 1190-1194. | 2.0 | 24 |
| 85 | Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. Breast Cancer Research and Treatment, 2014, 147, 113-118. | 1.1 | 24 |
| 86 | Parkinson disease ( PARK ) genes are somatically mutated in cutaneous melanoma. Neurology: Genetics, 2016, 2, e70. | 0.9 | 24 |
| 87 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362. | 1.4 | 23 |
| 88 | Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316. | 1.1 | 22 |
| 89 | The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecologic Oncology, 2010, 119, 511-515. | 0.6 | 21 |
| 90 | Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients. Carcinogenesis, 2017, 38, 1112-1118. | 1.3 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. Phytotherapy Research, 2017, 31, 1607-1613. | 2.8 | 21 |
| 92 | Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation. Breast Cancer Research and Treatment, 2011, 129, 557-563. | 1.1 | 20 |
| 93 | Bloom syndrome and Fanconi's anemia: rate and ethnic origin of mutation carriers in Israel. Israel Medical Association Journal, 2002, 4, 95-7. | 0.1 | 20 |
| 94 | The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Research and Treatment, 2018, 172, 151-157. | 1.1 | 19 |
| 95 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192. | 2.9 | 19 |
| 96 | Molecular analyses of the vasopressin type 2 receptor and aquaporin-2 genes in Brazilian kindreds with nephrogenic diabetes insipidus. , 1999, 14, 233-239. | | 18 |
| 97 | Prenatal diagnosis of a novelCOL1A1 mutation in osteogenesis imperfecta type I carried through full term pregnancy. Prenatal Diagnosis, 2000, 20, 876-880. | 1.1 | 18 |
| 98 | Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Research and Treatment, 2012, 133, 1153-1157. | 1.1 | 18 |
| 99 | The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genetics, 2016, 209, 50-52. | 0.2 | 18 |
| 100 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401. | 0.6 | 18 |
| 101 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134. | 1.1 | 18 |
| 102 | Recapitulating the clinical scenario of BRCAâ€associated pancreatic cancer in preâ€clinical models. International Journal of Cancer, 2018, 143, 179-183. | 2.3 | 18 |
| 103 | Genetic counseling in hereditary breast/ovarian cancer in Israel: Psychosocial impact and retention of genetic information. American Journal of Medical Genetics Part A, 2002, 111, 147-151. | 2.4 | 17 |
| 104 | Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. Genetical Research, 2013, 95, 174-177. | 0.3 | 17 |
| 105 | GREM1 germline mutation screening in Ashkenazi Jewish patients with familial colorectal cancer. Genetical Research, 2015, 97, e11. | 0.3 | 17 |
| 106 | The Genetics of Bene Israel from India Reveals Both Substantial Jewish and Indian Ancestry. PLoS ONE, 2016, 11, e0152056. | 1.1 | 17 |
| 107 | Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 353-359. | 0.4 | 17 |
| 108 | Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews. European Journal of Human Genetics, 1999, 7, 555-559. | 1.4 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. Genetical Research, 2014, 96, e002. | 0.3 | 16 |
| 110 | The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737. | 1.1 | 16 |
| 111 | Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel. Breast Cancer Research and Treatment, 2016, 155, 133-138. | 1.1 | 15 |
| 112 | Long-term remission of disseminated parathyroid cancer following immunotherapy. Endocrine, 2020, 67, 204-208. | 1.1 | 15 |
| 113 | Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1332-1340. | 0.4 | 15 |
| 114 | Novel candidate genes putatively involved in stress fracture predisposition detected by whole-exome sequencing. Genetical Research, 2014, 96, e004. | 0.3 | 14 |
| 115 | Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2015, 150, 631-635. | 1.1 | 14 |
| 116 | Germline Mutations in Familial Papillary Thyroid Cancer. Endocrine Pathology, 2020, 31, 14-20. | 5.2 | 14 |
| 117 | Activating genomic alterations in the Gs alpha gene (<scp>GNAS</scp>) in 274â€‰694 tumors. Genes Chromosomes and Cancer, 2020, 59, 503-516. | 1.5 | 14 |
| 118 | Candidate gene analysis in israeli soldiers with stress fractures. Journal of Sports Science and Medicine, 2012, 11, 147-55. | 0.7 | 14 |
| 119 | Prophylactic oophorectomy: Clinical considerations. Journal of Surgical Oncology, 2000, 19, 20-27. | 1.4 | 13 |
| 120 | Haplotype of the C61GBRCA1Mutation in Polish and Jewish Individuals. Genetic Testing and Molecular Biomarkers, 2009, 13, 465-469. | 0.3 | 13 |
| 121 | Cell phone use is associated with an inflammatory cytokine profile of parotid gland saliva. Journal of Oral Pathology and Medicine, 2016, 45, 682-686. | 1.4 | 13 |
| 122 | Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members ofAMelanoma Families. Journal of Investigative Dermatology, 2016, 136, 1066-1069. | 0.3 | 13 |
| 123 | Androgen Receptor CAG Repeat Size is Associated with Stress Fracture Risk: A Pilot Study. Clinical Orthopaedics and Related Research, 2011, 469, 2925-2931. | 0.7 | 12 |
| 124 | Germline mutations in RAD51C in Jewish high cancer risk families. Breast Cancer Research and Treatment, 2012, 136, 869-874. | 1.1 | 12 |
| 125 | The genetic history of Cochin Jews from India. Human Genetics, 2016, 135, 1127-1143. | 1.8 | 12 |
| 126 | Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel. Breast Cancer Research and Treatment, 2017, 166, 881-885. | 1.1 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276. | 2.9 | 12 |
| 128 | Common Susceptibility Loci for Male Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 453-461. | 3.0 | 12 |
| 129 | The spectrum of tumors harboring BAP1 gene alterations. Cancer Genetics, 2021, 256-257, 31-35. | 0.2 | 12 |
| 130 | p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 849-854. | 1.1 | 11 |
| 131 | Analysis of BRCA1/BRCA2 genesâ€™ contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Familial Cancer, 2009, 8, 127-133. | 0.9 | 11 |
| 132 | Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. European Journal of Human Genetics, 2018, 26, 382-386. | 1.4 | 11 |
| 133 | Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Israel Medical Association Journal, 2007, 9, 791-6. | 0.1 | 11 |
| 134 | Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). European Journal of Human Genetics, 1998, 6, 176-180. | 1.4 | 10 |
| 135 | Next generation sequencing for newborn screening: are we there yet?. Genetical Research, 2015, 97, e17. | 0.3 | 10 |
| 136 | Genotyping of geographically diverse Druze trios reveals substructure and a recent bottleneck. European Journal of Human Genetics, 2015, 23, 1093-1099. | 1.4 | 10 |
| 137 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801. | 1.1 | 10 |
| 138 | Breast cancer surveillance for BRCA1/2 mutation carriers â€“ is â€œearly detectionâ€•early enough?. Breast, 2020, 49, 81-86. | 0.9 | 10 |
| 139 | Germline variant in REXO2 is a novel candidate gene in familial pheochromocytoma. Genetical Research, 2020, 102, e3. | 0.3 | 10 |
| 140 | Somatic Mutation Analysis of theAPPandPresenilin 1and2Genes in Alzheimer's Disease Brains. Journal of Neurogenetics, 1998, 12, 55-65. | 0.6 | 9 |
| 141 | The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. Familial Cancer, 2012, 11, 243-247. | 0.9 | 9 |
| 142 | Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique forBRCA1/2mutation carriers. Psycho-Oncology, 2015, 24, 726-731. | 1.0 | 9 |
| 143 | Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers. Journal of Genetic Counseling, 2017, 26, 1070-1079. | 0.9 | 9 |
| 144 | Young Israeli women with epithelial ovarian cancer: prevalence ofBRCAmutations and clinical correlates. Journal of Gynecologic Oncology, 2017, 28, e61. | 1.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel. Breast Cancer Research and Treatment, 2018, 167, 697-702. | 1.1 | 9 |
| 146 | Streptococcus bovis bacteremia and underlying gastrointestinal neoplasms. Medical and Pediatric Oncology, 1986, 14, 313-315. | 1.0 | 8 |
| 147 | Exclusion of the phosphoinositide-specific phospholipase C?3 ( PLCB3 ) gene as a candidate for multiple endocrine neoplasia type 1. Human Genetics, 1996, 99, 130-132. | 1.8 | 8 |
| 148 | Adrenal tumors inBRCA1/BRCA2 mutation carriers. American Journal of Medical Genetics Part A, 2001, 98, 277-279. | 2.4 | 8 |
| 149 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126. | 1.1 | 8 |
| 150 | Riskâ€reducing salpingoâ€oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2 â€mutation carriersâ€"an Israeli matchedâ€pair study. International Journal of Gynecology and Obstetrics, 2021, , . | 1.0 | 8 |
| 151 | Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertility and Sterility, 2021, 116, 538-545. | 0.5 | 8 |
| 152 | Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers. Israel Medical Association Journal, 2017, 19, 365-367. | 0.1 | 8 |
| 153 | Non-Hodgkin's lymphoma complicating acute lymphoblastic leukemia in remission. Medical and Pediatric Oncology, 1988, 16, 132-134. | 1.0 | 7 |
| 154 | The Founder Mutations in theBRCA1,BRCA2, andATMGenes in Moroccan Jewish Women with Breast Cancer. Genetic Testing and Molecular Biomarkers, 2000, 4, 403-407. | 1.7 | 7 |
| 155 | Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like Families. Familial Cancer, 2005, 4, 291-294. | 0.9 | 7 |
| 156 | The P1812A and P25TBRCA1and the 5164del4BRCA2Mutations: Occurrence in High-Risk Non-Ashkenazi Jews. Genetic Testing and Molecular Biomarkers, 2006, 10, 200-207. | 1.7 | 7 |
| 157 | Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?. Breast Cancer Research and Treatment, 2012, 132, 669-673. | 1.1 | 7 |
| 158 | Whole-exome identifies RXRG and TH germline variants in familial isolated prolactinoma. Cancer Genetics, 2016, 209, 251-257. | 0.2 | 7 |
| 159 | Differential analysis of mutations in the Jewish population and their implications for diseases. Genetical Research, 2017, 99, e3. | 0.3 | 7 |
| 160 | Trends in the incidence of primary brain, central nervous system and intracranial tumors in Israel, 1990â€"2015. Cancer Epidemiology, 2018, 56, 6-13. | 0.8 | 7 |
| 161 | The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2019, 178, 231-237. | 1.1 | 7 |
| 162 | Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. Breast Cancer Research and Treatment, 2019, 176, 165-170. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | <p>Clinical Characteristics and Prognosis of Gastric Cancer Patients with <em>BRCA 1/2</em> Germline Mutations: Report of Ten Cases and a Literature Review</p>. OncoTargets and Therapy, 2020, Volume 13, 11637-11644. | 1.0 | 7 |
| 164 | Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. Breast Cancer Research and Treatment, 2020, 181, 445-453. | 1.1 | 7 |
| 165 | Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 185, 391-399. | 1.1 | 7 |
| 166 | Malignant peritoneal mesothelioma: Long-term spontaneous clinical remission. Medical and Pediatric Oncology, 1991, 19, 325-328. | 1.0 | 6 |
| 167 | Mutation analysis of the MEN1 gene in Israeli patients with MEN1 and familial isolated hyperprolactinemia. Human Mutation, 2000, 16, 269-269. | 1.1 | 6 |
| 168 | The 1100delAT BRCA1 and the 8765delAG BRCA2 Mutations: Occurrence in High-Risk Non-Ashkenazi Jews and Haplotype Comparison of Jewish and Non-Jewish Carriers. Familial Cancer, 2002, 3, 11-14. | 0.9 | 6 |
| 169 | Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. Familial Cancer, 2009, 8, 473-478. | 0.9 | 6 |
| 170 | Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. Journal of Clinical Oncology, 2016, 34, e61-e67. | 0.8 | 6 |
| 171 | Molecular and immunohistochemical analyses of uveal melanoma patient cohort. Melanoma Research, 2019, 29, 248-253. | 0.6 | 6 |
| 172 | Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity. Anticancer Research, 2017, 37, 3069-3072. | 0.5 | 6 |
| 173 | Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers. BMC Cancer, 2022, 22, . | 1.1 | 6 |
| 174 | Mutational Analyses of Candidate Genes in Human Squamous Cell Carcinomas. Laryngoscope, 1999, 109, 661-663. | 1.1 | 5 |
| 175 | SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women. Familial Cancer, 2009, 8, 135-144. | 0.9 | 5 |
| 176 | FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns. Genetical Research, 2014, 96, e11. | 0.3 | 5 |
| 177 | Mutational analysis of candidate genes in Israeli male breast cancer cases. Breast Cancer Research and Treatment, 2018, 170, 399-404. | 1.1 | 5 |
| 178 | The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients. Cancer Causes and Control, 2019, 30, 97-101. | 0.8 | 5 |
| 179 | De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer. Familial Cancer, 2020, 19, 193-196. | 0.9 | 5 |
| 180 | A novel MSH2 germline mutation in a Druze HNPCC family. Familial Cancer, 2008, 7, 135-139. | 0.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | DNA Base-Excision Repair Genes OGG1 and NTH1 in Brazilian Lung Cancer Patients. Molecular Diagnosis and Therapy, 2015, 19, 389-395. | 1.6 | 4 |
| 182 | Malignant phenotype and two SDHD mutations in a family with paraganglioma syndrome type 1. Genetical Research, 2015, 97, e3. | 0.3 | 4 |
| 183 | Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma. In Vivo, 2018, 32, 1527-1531. | 0.6 | 4 |
| 184 | Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study. Cancer Biomarkers, 2020, 28, 269-273. | 0.8 | 4 |
| 185 | Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications. Breast Cancer Research and Treatment, 2021, 188, 685-694. | 1.1 | 4 |
| 186 | Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant. Familial Cancer, 2022, 21, 305-308. | 0.9 | 4 |
| 187 | Mutational Analysis of the hMSH6 Gene in Familial and Early-Onset Colorectal and Endometrial Cancer in Israeli Patients. Genetic Testing and Molecular Biomarkers, 2002, 6, 323-326. | 1.7 | 3 |
| 188 | The CYP17A1 â^'34TÂ>ÂC polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 521-527. | 1.1 | 3 |
| 189 | De novo mutation in MEN1 is not associated with parental somatic mosaicism. Endocrine-Related Cancer, 2017, 24, L1-L3. | 1.6 | 3 |
| 190 | Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention. Menopause, 2020, 27, 82-87. | 0.8 | 3 |
| 191 | Postâ€mastectomy surveillance of BRCA1 / BRCA 2 mutation carriers: Outcomes from a specialized clinic for highâ€risk breast cancer patients. Breast Journal, 2021, 27, 441-447. | 0.4 | 3 |
| 192 | Reâ€evaluating the pathogenicity of the c.783+2T>C BAP1 germline variant. Human Mutation, 2021, 42, 592-599. | 1.1 | 3 |
| 193 | Genetic association of the PERIOD3 (PER3) Clock gene with extreme obesity. Obesity Research and Clinical Practice, 2021, 15, 334-338. | 0.8 | 3 |
| 194 | Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers.. Journal of Clinical Oncology, 2013, 31, 278-278. | 0.8 | 3 |
| 195 | Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel. JAMA Network Open, 2021, 4, e2139670. | 2.8 | 3 |
| 196 | A germline mutation in the Von Hippel-Lindau disease gene (L178Q) detected by denaturing gradient gel electrophoresis in a large Jewish-Yemenite family. Human Mutation, 1999, 14, 448-448. | 1.1 | 2 |
| 197 | The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genetics, 2016, 209, 283-284. | 0.2 | 2 |
| 198 | Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic. Clinical Breast Cancer, 2018, 18, e695-e698. | 1.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Are VNTRs co-localizing with breast cancer-associated SNPs?. Breast Cancer Research and Treatment, 2018, 168, 277-281. | 1.1 | 2 |
| 200 | Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations. Breast Cancer Research and Treatment, 2021, 186, 259-263. | 1.1 | 2 |
| 201 | Automated Breast Volumetric Sonography Compared with Magnetic Resonance Imaging in Jewish BRCA 1/2 Mutation Carriers. Israel Medical Association Journal, 2016, 18, 609-612. | 0.1 | 2 |
| 202 | The m2 and m4 polymorphisms in CYP1A1 by NcoI digest?Revision of detection method. Human Mutation, 2000, 15, 120-120. | 1.1 | 1 |
| 203 | Colonic Adenomas Do Not Cosegregate with the I1307K APC Missense Mutation in an Israeli Non-Ashkenazi Family. Digestive Diseases and Sciences, 2005, 50, 52-55. | 1.1 | 1 |
| 204 | Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 131, 981-985. | 1.1 | 1 |
| 205 | Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel. Anticancer Research, 2018, 38, 4557-4563. | 0.5 | 1 |
| 206 | Co-occurrence ofMEN1p.Gly111fs andAIPp.Arg16His Variants in Familial MEN1 Phenotype. Anticancer Research, 2018, 38, 3683-3687. | 0.5 | 1 |
| 207 | Genetic Analysis of Brazilian Patients with Gallbladder Cancer. Pathology and Oncology Research, 2019, 25, 811-814. | 0.9 | 1 |
| 208 | Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors. Familial Cancer, 2020, 20, 189-194. | 0.9 | 1 |
| 209 | Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population. Cancer, 2021, 127, 3599-3604. | 2.0 | 1 |
| 210 | Populationâ€based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants. Molecular Genetics & Genomic Medicine, 2022, , e1928. | 0.6 | 1 |
| 211 | Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic. Academic Radiology, 2022, , . | 1.3 | 1 |
| 212 | A neutral polymorphism (c1088C>T) in the estrogen receptor detected by DGGE. Human Mutation, 1999, 13, 507-507. | 1.1 | 0 |
| 213 | Risk-reducing salpingo-oophorectomy and breast cancer incidence among BRCA-mutation carriers.. Journal of Clinical Oncology, 2021, 39, 10548-10548. | 0.8 | 0 |
| 214 | Genetic testing for assessment of lynch syndrome in young patients with polyps. Digestive and Liver Disease, 2021, 53, 1640-1646. | 0.4 | 0 |
| 215 | Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2016, 34, 244-244. | 0.8 | 0 |
| 216 | The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <scp>BRCA2 6174delT</scp>. Clinical Genetics, 2022, 101, 317-323. | 1.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Abstract P2-09-16: Clinicopatological features and outcome of breast cancer in CHEK2 germline mutation carriers. Cancer Research, 2022, 82, P2-09-16-P2-09-16. | 0.4 | 0 |